Changes in Beneficial Ownership · 4
Roivant Sciences Ltd.
ROIVNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-16
- Issuer
- Roivant Sciences Ltd.
- Issuer CIK
- 0001635088
- Trading symbol
- ROIV
Reporting owner 1
- Name
- QVT Financial LP
- Reporting owner CIK
- 0001290162
- Relationship
- Other
- Other relationship
- Director by Deputization
- Address
- 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK, NY, 10106
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | 2026-11-16 | S · Form 4 | 79,461 | D | 39.17 | 13,609,705 | I[F1] | Held by QVT Financial Investment Cayman Ltd.[F2] |
| Common Shares | 2026-11-16 | S · Form 4 | 550,280 | D | 39.17 | 1,042,200 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd[F2] |
| Common Shares | 2026-11-16 | S · Form 4 | 18,927 | D | 38.99 | 13,590,778 | I[F1] | Held by QVT Financial Investment Cayman Ltd.[F2] |
| Common Shares | 2026-11-16 | S · Form 4 | 131,073 | D | 38.99 | 911,127 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd[F2] |
| Common Shares | 2026-11-17 | J · Form 4[F3] | 2,635,169 | D | 0.00 | 5,806,259 | I[F1] | Held by QVT Deferred Compensation Holdings Ltd.[F2] |
| Common Shares | 2026-11-17 | J · Form 4[F3] | 15,969 | D | 0.00 | 13,574,809 | I[F1] | Held by QVT Financial Investment Cayman Ltd.[F2] |
| Common Shares | 2026-11-17 | J · Form 4[F3] | 385,620 | D | 0.00 | 525,507 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd[F2] |
| Common Shares | 2026-11-17 | S · Form 4 | 75,716 | D | 38.24 | 13,499,093 | I[F1] | Held by QVT Financial Investment Cayman Ltd.[F2] |
| Common Shares | 2026-11-17 | S · Form 4 | 525,507 | D | 38.24 | 0 | I[F1] | Held by QVT P&E Roiv Hldgs Ltd[F2] |
| Common Shares | 2026-11-17 | S · Form 4 | 798 | D | 38.24 | 5,805,461 | I[F1] | Held by QVT Deferred Compensation Holdings Ltd.[F2] |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Disposed
- I
- Indirect
- J · Form 4
- Other acquisition or disposition; see explanation
Footnotes
- F1
- Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 19,304,554 Common Shares, consisting of the Common Shares owned by QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC, a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
- F2
- QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10
Signature 1
- Signed
- /s/ Meg Eisner
- Date
- 2026-11-18
Company context
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.